Indication
B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell progenitor lymphoblasts within the bone marrow and peripheral blood. Read more about B-cell acute lymphoblastic leukemia
7 drugs 5 manufacturers
Drugs that treat it
Common B-cell acute lymphoblastic leukemia therapies.
BLINCYTO (blinatumomab)
BLINCYTO (blinatumomab)
KYMRIAH (tisagenlecleucel)
TECARTUS (brexucabtagene autoleucel)
AUCATZYL (obecabtagene autoleucel)
KYMRIAH (tisagenlecleucel)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonB-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell progenitor lymphoblasts within the bone marrow and peripheral blood.
It is the most common subtype of acute lymphoblastic leukemia, predominantly affecting young children while also occurring in adults.
Pathophysiologically, recurring genetic and chromosomal alterations disrupt normal lymphoid differentiation, leading to marrow infiltration and secondary cytopenias that clinically manifest as fatigue from anemia, recurrent infections, and bleeding or bruising from thrombocytopenia, often alongside hepatosplenomegaly, lymphadenopathy, or extramedullary involvement.
- cancer.gov
B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell progenitor lymphoblasts within the bone marrow and peripheral blood It is the most common subtype of acute lymphoblastic leukemia, predominantly affecting young children while also occurring in adults
- nih.gov
B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell progenitor lymphoblasts within the bone marrow and peripheral blood Pathophysiologically, recurring genetic and chromosomal alterations disrupt normal lymphoid differentiation, leading to marrow infiltration and secondary cytopenias that clinically manifest as fatigue from anemia, recurrent infections, and bleeding or bruising from thromb...
- nih.gov
It is the most common subtype of acute lymphoblastic leukemia, predominantly affecting young children while also occurring in adults
- leukemiarf.org
It is the most common subtype of acute lymphoblastic leukemia, predominantly affecting young children while also occurring in adults Pathophysiologically, recurring genetic and chromosomal alterations disrupt normal lymphoid differentiation, leading to marrow infiltration and secondary cytopenias that clinically manifest as fatigue from anemia, recurrent infections, and bleeding or bruising from thrombocytopenia, often alongside hepatosplenomegaly, lymphadenopathy, or extramedullary involvement
- nih.gov
Pathophysiologically, recurring genetic and chromosomal alterations disrupt normal lymphoid differentiation, leading to marrow infiltration and secondary cytopenias that clinically manifest as fatigue from anemia, recurrent infections, and bleeding or bruising from thrombocytopenia, often alongside hepatosplenomegaly, lymphadenopathy, or extramedullary involvement
Personalize your experience
Follow B-cell acute lymphoblastic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.